Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

saruparib (AZD5305)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

PARP1 inhibitor

Related drugs:

BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D
HRD	HER2 Positive Breast Cancer	HRD	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive: D – Preclinical fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive : D	fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive: D – Preclinical fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive : D
HRD	Colorectal Adenocarcinoma	HRD	Colorectal Adenocarcinoma	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D
HRD	Breast Cancer	HRD	Breast Cancer	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D
VTCN1 underexpression	Solid Tumor	VTCN1 underexpression	Solid Tumor	AZD8205 + AZD5305 Sensitive: D – Preclinical AZD8205 + AZD5305 Sensitive : D	AZD8205 + AZD5305 Sensitive: D – Preclinical AZD8205 + AZD5305 Sensitive : D